Gilead could make as much as $7.6 billion in 2022 off its promising COVID-19 treatment remdesivir, according to Wall Street analyst Leerink.
According to media reports, Leerink suggests Gilead will sell treatment rounds of the drug for $5,000 in the U.S., which is slightly higher than the max price recommended by the Institute for Clinical and Economic Review.
“This forecast has more uncertainty than any that we have published in the last 15 years, but it reflects our view that remdesivir works, it saves medical and societal costs by shortening disease duration and reducing severity, and we believe that Gilead will be permitted to capture reduced but still real profitability from the product,” Leerink analyst Geoffrey Porges said.
To read a report by Inside Health Policy, click here.
